Login / Signup

Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.

Toshio ShimizuKazuto NishioKazuko SakaiIsamu OkamotoKunio OkamotoMasayuki TakedaMaiko MorishitaKazuhiko Nakagawa
Published in: Cancer chemotherapy and pharmacology (2020)
UMIN000031912 at UMIN Clinical Trials Registry (UMIN-CTR).
Keyphrases
  • advanced non small cell lung cancer
  • epidermal growth factor receptor
  • clinical trial
  • tyrosine kinase
  • small cell lung cancer
  • randomized controlled trial
  • anti inflammatory
  • phase iii